Limburg Ventures
VC Fund
Maastricht, The Netherlands
Limburg Ventures is a venture capital fund that invests in startups in life sciences and related fields of advanced chemicals and materials.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Limburg Ventures invests in
BiotechnologyHealth CareLife ScienceMedicalGenetics
Stages Limburg Ventures invests in
Funding RoundSeries ASeries BSeedSeries C
Countries Limburg Ventures invests in
The NetherlandsFranceBelgiumGermanyUnited Kingdom
Round sizes
Series A $2.2M–$3.3MSeries B $1.9M–$5.5M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Series A
- $2.2M–$3.3M
- Series B
- $1.9M–$5.5M
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 4 (31%)
- Life Science 4 (31%)
- Medical 3 (23%)
- Genetics 3 (23%)
Stage
- Funding Round 4 (31%)
- Series A 3 (23%)
- Series B 3 (23%)
- Seed 1 (8%)
- Series C 1 (8%)
Country
- The Netherlands 8 (62%)
- France 1 (8%)
- Belgium 1 (8%)
- Germany 1 (8%)
- United Kingdom 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Marcel Kloosterman
Senior Investment Manager
|
Senior Investment Manager | Total investments: 6 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ReSolved Technologies
|
ReSolved Technologies are dedicated to increase the circularity of engineering plastics by addressing complex waste streams. They do this by extracting valuable plastics from these difficult-to-recycle waste streams and convert them to recycled material of near-virgin quality that is suited for closed-loop recycling in high-end markets. | $1.1M / Seed / Aug 28, 2023 | |
Kriya Materials
|
Kriya Materials is the innovative developer and manufacturer of various metal oxide nano particles as well as their downstream dispersions and functional coating products thereof. Coatings play an important role in our everyday life, although often not recognized by those who do not master the art. Coatings are a big market and many products fallunder this category. Kriya Materials focuses itself on the development and manufacturing of various nano metal oxides which it uses internally for the development and production of very high end coatings.The coatings made by Kriya Materials are applied in a wide range of markets, some examples are the Plasma Panel and LCD industry, from Smartphone to touch panels to glass surfaces. | $3.3M / Series A / Sep 13, 2017 | |
Enzypep
|
Enzypep designs and develops oligopeptides for pharmaceutical products. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable,environmentally-friendly manner. It began operation in 2012, with its headquarters in Geleen in the Netherlands. | Jan 01, 2014 | |
Ekompany
|
Ekompany is a Dutch producer of coated mineral fertilisers (CRF) with sales operations in Western Europe and Far East. Their team of professionals possesses the latest knowledge across the chemical, agricultural and horticultural fields and have decades of experience in designing, producing and supplying specialty fertilisers supported by the rightadvice.Established in 2010, their unique production facility in Born was opened for production in September 2013. Ekompany has developed a patented coating process that is clean, safe, continuous and more energy efficient than existing ones. This way they can produce intelligent Controlled Release Fertilisers that are both technologically advanced and economical for wider use in agriculture and horticulture. Learn more about their Ekote portfolio which has proven its benefits in more than 200 field trials internationally. | $12.3M / Mar 06, 2013 | |
BioActor
|
BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All these ingredients address chronic health concerns, such as diabetes,osteoporosis, cardiovascular disease, that would benefit from preventative measures through the diet. BioActor's product development strategy relies onthree simple tenets: a new health ingredient must be based on a patentable scientific discovery; it must be food grade from a natural and renewable source; and its health effect must be clinically proven. BioActor's first product, BONOLIVE, a first in class bone health ingredient that is clinically proven to stimulate bone producing cells, is a great example of this strategy and will be launched in the USA this year. BioActor successfully implemented its product development strategy by establishing alliances with top nutrition research institutes (e.g. INRA, CSIC, Maastricht University, UCL, Ghent University) and by establishing production partnerships with industrial players to shorten the path to market. | $2.2M / Series A / Jul 26, 2011 | |
Q Chip
|
Q Chip is a biopharmaceutical drug delivery company developing a range of sustained-release biogeneric and biotherapies products (Q-Spheraâ„¢). | $6M / Series C / May 20, 2011 | |
MagnaMedics
|
MagnaMedics engineers and produces magnetic nano- and microparticles that are used in medical devices, drug delivery tools and diagnostic kits. Diagnostic kits are used for determination of biomarkers in body fluids; the company focuses on proteomics and more specifically on high-quantity isolation of proteins as well as on research customersactive in high-throughput screening of biomarkers. | Series B / Feb 01, 2011 | |
CellMade
|
CellMade develops and commercializes cell biology products and services: human-origin primary cells, co-culture models, customized cell isolation and characterization. CellMade also invests in its own R&D program using its CellInsight platform for identification of targets and biomarkers related to inflammatory pathologies. The company hasfacilities in Marseille (France) and at the Chemelot Campus. | $1.8M / Oct 01, 2010 | |
FABPulous
|
FABPulous is an innovative healthcare company which develops and markets solutions for diagnostics in primary care and emergency medicine.FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, HealthInnovations, Limburg Ventures and NV Industriebank LIOF.The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction. | Series A / Jan 11, 2010 | |
TiGenix
|
TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, forthese indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd. | $7.5M / Private Equity / Jun 25, 2009 | |
| See all 13 investments → | |||
Co-Investors
NV Industriebank LIOF
5 deals together
Nedermaas Hightech Ventures
4 deals together
Chemelot Ventures
3 deals together
Health Innovation Fund
2 deals together
Thuja Capital
2 deals together
ABN AMRO Fund
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Life Science Investors
6,823 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
FAQ
What does Limburg Ventures invest in?
Limburg Ventures invests primarily in Biotechnology, Health Care and Life Science startups, most often at Funding Round and Series A stage. Most of the 13 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Limburg Ventures's check size?
Limburg Ventures typically joins rounds of $2.2M–$3.3M at Series A and $1.9M–$5.5M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Limburg Ventures participates in.
How do I contact Limburg Ventures?
Public channels for Limburg Ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Limburg Ventures?
The team at Limburg Ventures includes Marcel Kloosterman (Senior Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
